Integrative Cancer Therapy Fellowship


Of the approximately 1,658,370 people newly diagnosed with cancer each year, 589,430 will not survive.

Yet despite these ominous numbers, the science of oncology advances much more rapidly than the actual practice and application of oncology. Physicians and health care practitioners across the globe have not only been faced with this widespread disease, but have also felt hopeless when it has infiltrated their personal lives. The overwhelming statistics of mortality have increased public awareness regarding the search for alternative cancer treatments.

Integrative Cancer Therapy is a vital and ever-changing topic in today’s medical industry, and preventive medicine often focuses on cancer methodologies and treatments. Recent innovative and exciting advances in the treatment of advanced-stage cancers are collectively vital to an integrative practitioner’s toolbox. The gap in updated cancer education has further spurred the growing need for the implementation of Integrative Cancer Therapy education nationwide.

What is Integrative Cancer Treatment (ICT)?

Integrative Cancer Treatment is a unique therapy for treating individuals with cancer, which utilizes multiple modalities including, off-label pharmaceuticals, nutraceuticals, vaccines and other types of immunotherapy, novel drugs/substances, dietary treatments, mind-body techniques, hyperthermia, and homeopathy.


Why this Fellowship?


All healthcare practitioners, not solely oncologists, have patients who are affected by cancer. Our Fellowship in Integrative Cancer Therapy is designed to teach cutting-edge methods needed to improve the quality of life for your patients. Cancer researcher and integrative medicine practitioner Dr. Mark Rosenberg discusses new protocols for treating cancer, including methods of merging this new revenue stream into your practice. The innovative curriculum instructs participants on cancer prevention methods, the ways in which cancer functions and manifests, in-depth patient case studies, and a variety of integrative cancer treatment protocols that can be integrated into your practice. Cancer research is expanding each day: be at the forefront of scientific education, and be the difference your patients need.


Modules I-VIII (listed below) must be completed to successfully earn the ICT fellowship, and they can be completed in any order.

  • Completion of Modules I-VIII
  • Active Membership
  • Photocopy of your Medical Degree
  • Photocopy of Active Medical License
  • A 5 Year CV, demonstrating at least 5 years of clinical practice
  • 200 CME hours over the past 8 years
  • Signed affidavit of no disciplinary action
Become a Part of the Future of Cancer Management

If you have any questions, or need assistance regarding requirements or graduation, please contact the board registrar at boards@a4m.com

ICT Fellowship Modules I-VIII*

*This program is only available online.

Staff and Faculty:

Mark Rosenberg, MD

Mark Rosenberg, MD

Dr. Rosenberg has been involved with drug research since 1991. Having studied the mechanisms of cancer treatment failure, the following concept has become blatantly apparent to Dr. Rosenberg.

There are many substances that are toxic to cancer cells in vitro (outside of the body, in a culture medium), including chemotherapy and intravenous antioxidant therapy. These therapies, however, are more often then not, ineffective in vivo (inside the body). The primary reason for the ineffectiveness is that tumor blood flow is poor, resulting in a tumor that actually receives very little of the cytotoxic therapy that is being administered. In addition, poor tumor blood flow is associated with higher grade tumors and greater incidence of metastasis.
Dr. Rosenberg has since concentrated his efforts on improving blood flow to the cancer, while administering cytotoxic intravenous antioxidant therapy. In addition to using vasodilating therapy such as carbogen and isosorbide dinitrate, Dr. Rosenberg has just been granted approval status for an IND (investigational new drug) using Angiotensin II. Angiotensin II is frequently used in Japan in conjunction with chemotherapy to improve tumor blood flow.
Dr. Rosenberg recently appeared on Fox News in 2006, for inducing remission on a patient with metastatic lung cancer (to liver and spine) that was refractory to chemotherapy.

Stephen Hoption Cann, PhD

Stephen Hoption Cann, PhD

Stephen A. Hoption Cann,Ph.D serves as Chief Scientific Officer of MBVax Bioscience Inc. Dr. Hoption is an Assistant Professor in the Department of Health Care & Epidemiology at the University of British Columbia.

His research interests include the epidemiology of cancer, the phenomenon of spontaneous regression of cancer, and the work of Dr. William Coley. Dr. Hoption Cann has published 21 peer-reviewed papers, is a reviewer for Postgraduate Medical Journal and Medical Science Monitor: International Medical Journal of Experimental & Clinical Research, and is a Member of the American Association for Cancer Research.

Isaac Eliaz, MD,  L.Ac., M.S.

Isaac Eliaz, MD, L.Ac., M.S.

Author, lecturer, researcher, formulator, practitioner, and pioneer of integrative medicine, Dr. Eliaz founded the Amitabha Clinic in Sebastopol, California. He is the pioneering force behind the development of Modified Citrus Pectin and poly-botanical formulas for the prevention and treatment of cancer and toxin removal. He has spearheaded extensive peer-reviewed research.

Leonardo Gonzalez,  MD

Leonardo Gonzalez, MD

Dr. Leonardo Gonzalez is a Board Certified Radiologist. He received his radiology specialty training at The University of Pennsylvania. Dr. Gonzalez completed a neuro-radiology fellowship at the Lucile Packard Children's Hospital at Stanford University in Palo Alto, CA.

Dr. Gonzalez spent an additional 2 years in the specialty of Anti-Aging and Regenerative Medicine. He just completed the Fellowship in Anti-Aging and Regenerative Medicine. That extensive training has created demand not only for his radiological skill but also creates many requests from his colleagues for his instructorship. Dr. Gonzalez has taught in South America and across the U.S.

Dr. Gonzalez is the President of The Institute for Healthy Aging of Latin America. He is currently participating in the creation of an Integrative Cancer Therapy and biological medications development along with Dr. Mark Rosenberg.

Michael J. Gonzalez, MD

Michael J. Gonzalez, MD

Professor at the Nutrition Program, School of Public Health in the Medical Sciences Campus, University of Puerto Rico

He earned a Bachelor Degree in Biology and Chemistry (Catholic University), a Masters in Cellular Biology and Biophysics (Nova University), and another Masters in Nutrition and Public Health (University of P.R.). He also has a Doctorate in Health Sciences (Lafayette University), and another Doctorate in Nutritional Biochemistry and Cancer Biology (Michigan State University). He completed a Post-Doctoral Fellowship in Geriatrics in the School of Medicine, University of Puerto Rico. Dr. Gonzalez is a Fellow of the American College of Nutrition, and has authored over 100 scientific publications. He is an active member on several scientific journal Editorial Boards, such as Biomedicina, the Journal of Orthomolecular Medicine, and Alternative Medicine Reviews. As a consultant for several companies, he has been responsible for designing formulations of nutritional supplements and pharmaceutical products. At present, he is a consultant for The Center for the Improvement of Human Functioning International, in Wichita, Kansas. He has obtained several research awards for his work on Nutrition and Cancer. He is currently Co-Director of RECNAC II project, and Research Director of the InBioMed Project Initiative.

Gar Hildenbrand

Gar Hildenbrand

Gar Hildenbrand is an epidemiologist with broad knowledge and experience in the evaluation of alternative methods of cancer management; he is also a federal policy expert and political activist for reform of the cancer industry.

As a whistle-blowing advisor to the U.S. Office of Technology Assessment (OTA), he exposed stealth "quackbusters" on the OTA staff and salvaged the study "Unconventional Cancer Treatments" (OTA-H-405;Sept 1990). Gar was appointed by Iowa Senator Tom Harkin to monitor the introduction of a coordinating office, the Office of Alternative Medicine, into Office of the Director of the National Institutes of Health, and was promptly labeled a "Harkinite" in the pages of Science. Gar chaired the chapter "Diet and Nutrition in the Prevention and Treatment of Chronic Disease" for the NIH publication Alternative Medicine: Expanding Medical Horizons, and chaired OAM's Strategic Planning Committee of the Alternative Medicine Program Advisory Council. He and his wife Christeene published the first retrospective outcomes report of any of the well-known alternative methods of cancer management, detailing 5-year survivals in melanoma patients treated with Gerson's Diet Therapy. A tireless advocate for fair evaluation of promising alternatives, Gar is currently conducting a Freedom of Information Act inquiry into FDA's long-term war against Coley Fluid, the first and by far most effective immunotherapeutic agent for cancer.

Michael Kasper, MD

Michael Kasper, MD

Dr. Kasper is a board certified Radiation Oncologist on staff at the Boca Raton Community Hospital, where he has practiced since 1993. He holds appointments as Clinical Assistant Prof at the University of Miami, Miller School of Medicine, and Florida Atlantic University, Department of Biomedical Science. He completed his residency at the University of Florida, where he also received his medical degree. He graduated with a B.S. in Psychology from Tufts University.

Dr. Kasper served as the Medical Director of the Eugene M. and Christine E. Lynn Clinical Research Center from 2003 until 2008 and is the hospital's principal investigator for the Radiation Therapy Oncology Group. He was appointed by Governors Bush and Crist to serve on Florida's Cancer Control and Research Advisory Board, which he chaired from 2005 - 2008. He currently serves as the Physician Liaison for the American College of Surgeons Committee on Cancer.

Dr. Kasper has been active in the community lecturing and volunteering for many organizations. He serves on the local and Division Boards of the American Cancer Society, as well as the ACS National Assembly. He is past President and Chairman of the Board of the Florida /Puerto Rico Division of the ACS. He has been a leading advocate for improving cancer care throughout the state by increasing research capacity and raising treatment standards. His advocacy work at the state level was instrumental in passage of Amendment 6, which made Florida workplaces smoke-free.

Aaron E. Katz, MD

Aaron E. Katz, MD

Dr. Aaron E. Katz is currently an Associate Professor of Clinical Urology and the Vice Chairman of Urology at Columbia University Medical Center. He has been a faculty member at Columbia since 1993. He also holds a title as the Director of the Center for Holistic Urology, a Center which he established in 1998. The Center performs basic research and conducts clinical trials which investigate the role of natural therapies within urology. Dr. Katz is currently serving as the Principle Investigator for numerous clinical trials.

After graduating from New York Medical College in 1986, Dr. Katz completed a 6 year training program in Brooklyn at the Maimonides Medical Center. Following the completion of his residency, Dr. Katz was awarded a Ferdinand Valentine Fellowship from the New York Academy of Medicine to further his studies in Urologic Oncology at Columbia University. During his Fellowship, Dr. Katz developed a novel blood test , which could detect small numbers of prostate cancer cells in the blood. The test known as RT-PCR (Reverse Transcriptase Polymerase Chain Reaction) was the first time urologic cancers were staged using a molecular assay. He has received several awards and grants to further his research.

Dr. Katz is also recognized as an expert in the field of prostate cryosurgery. In the early 1990's, he began using cryosurgery to cure prostate cancers. His pioneer work in advancing the technology helped Medicare approve of this therapy for treating radiation-recurrent tumors. Dr. Katz has trained nearly 100 urologists in the United States and Europe to perform cryosurgery in their hospital. In the field of cryosurgery Dr. Katz has published numerous articles, written chapters for medical textbooks, and directed courses at both regional and national levels. He has also applied cryosurgery to the treatment of small kidney tumors, and performed the ablation both percutaneously and laparascopically. Most recently, Dr. Katz was invited to host a show on cryosurgery for PBS television, which will air in March 2005.

To date, Dr. Katz has published over 90 scientific articles in peer-reviewed journals, and has written 4 chapters for Urologic textbooks. He is the author of two recently published books: 'Dr. Katz's Guide to Prostate Health: From Conventional to Holistic' and the "Handbook of Urologic Cryoablation'. He has been the host of a radio program called "Mens Health Talk" in New York City for several years and he has lectured extensively throughout the United States, Europe and Japan.
Dr. Katz has an office at the Columbia University Medical Center, as well as a convenient East Side office in Midtown Manhattan. He can be reached for consultation at (212) 305-0114. Medicare and several commercial insurances are accepted.

Khalid Mahmud, MD,  FACP

Khalid Mahmud, MD, FACP

Founder, Innovative Directions in Health - the only Anti-Aging Clinic in Minnesota. Board certified: Anti-Aging Medicine, Internal Medicine, Hematology and Oncology. Former chief of Medicine and Medical Director of Oncology, North Memorial Medical Center, Minneapolis. Frequent author, a national speaker. Author of the book, "Keeping aBreast: Ways to STOP Breast Cancer".

Dwight McKee, MD

Dwight McKee, MD

Dr. McKee graduated from Williams College with honors in chemistry in 1970. He then entered a combined M.D.-Ph.D. program at Case-Western Reserve University in Cleveland, Ohio, where he completed the first 2 years of medical school, as well as full graduate studies in pharmacology, and 1 year of research. After changing his interest from laboratory research to clinical medicine, he completed his last 2 years of medical school at the University of Kentucky, in Lexington Ky, where he received his M.D. degree in 1975. After a rotating internship at the Washington Hospital Center in Wash. D.C., he became associate medical director of Integral Health Services in Putnam, CT.—the first integrative medicine clinic on the east coast.

Over the next 12 years he studied and practiced nutritional and mind/body medicine, along with a full range of complementary medicine disciplines. Thru working with cancer patients in his practice, he became increasingly interested in cancer medicine, which led him in 1988 to return to hospital based post-graduate training in internal medicine at Los Angeles County Hospital, Santa Clara Valley medical center, and Stanford University. After becoming Board Certified in Internal Medicine, he completed a 3 years fellowship in Hematology and Oncology at the Scripps Clinic, in La Jolla, CA, and subsequently became Board Certified in both disciplines. He was also a Visiting Scientist at The Scripps Research Institute Immunology division for 2 years, where he pursued advanced studies in immunology, and performed laboratory research in tumor immunology. Since completing training in medical oncology, hematology, and immunology, Dr. McKee has been involved in the development of integrative cancer care, creating a synthesis between conventional cancer medicine and alternative/complementary medicine. In 2003 he became Board Certified in nutrition through the American College of Nutrition, and in 2007 he became Board Certified in Integrative and Holistic medicine through the American Board of Holistic Medicine In 2008 he co-authored a text book on Herb, Nutrient, and Drug Interactions, which is used as a text in most of the naturopathic colleges, at many medical schools, as well as by many integrative medical practitioners.

Jorge R. Miranda-Massari, MD

Jorge R. Miranda-Massari, MD

Professor at the School of Pharmacy in the Medical Sciences Campus, University of Puerto Rico, and a Registered Pharmacist

He earned two bachelor degrees at the University of Puerto Rico, one in Science and another in Pharmacy. After earning a Doctorate Degree in Pharmacy at the Philadelphia College of Pharmacy and Science, he completed a Post-Doctoral Fellowship in Clinical Pharmacokinetics at the University of North Carolina. He obtained Post-Doctoral training in Pharmaceutical Care in Nephrology from the University of Pittsburgh, and another one in Clinical Anti-Coagulation from the Medical College of Virginia. Author of numerous scientific publications including editorials, reviews and research data in peer review journals, Dr. Miranda-Massari is a consultant for the prestigious Center for the Improvement of Human Functioning International, in Wichita, Kansas. He is also Director of the Education Branch of the innovative InBioMed Project and Clinical Research Director of the RECNAC-II Project, specialized in Cancer Research. Over the last 10 years he has given hundreds of lectures to a diverse audience on the use of nutrients and botanicals. He is the creator of the first course in Integrative Medicine (Interdisciplinary Classification at a Doctoral Level), and the Advanced Practicum in Integrative Medicine, at the School of Pharmacy, Medical Sciences Campus of the University of Puerto Rico. Dr. Miranda-Massari received from the Puerto Rico College of Pharmacist the Innovative Pharmacist Award 2008.

Ralph W. Moss

Ralph W. Moss

The medical writer Ralph W. Moss, PhD, has written or edited twelve books and three film documentaries on questions relating to cancer research and treatment.

Moss is a graduate of New York University (BA, cum laude, Phi Beta Kappa, 1965) and Stanford University (MA, 1973, PhD, 1974, Classics). The former science writer and assistant director of public affairs at Memorial Sloan-Kettering Cancer Center in New York (1974-1977), for the past 35 years Moss has evaluated the claims of various conventional and non-conventional cancer treatments. He currently directs The Moss Reports, an up-to-date library of detailed reports on more than 200 varieties of cancer. Since 2001 he has published a weekly online newsletter that reaches more than 50,000 readers. Although not a medical doctor, he is noted for his critical acumen on health topics and is listed in Marquis Who's Who in America, Who's Who in the World, Who's Who in HealthCare, etc.

Moss is the author of such books as Antioxidants Against Cancer, Cancer Therapy, Questioning Chemotherapy, and The Cancer Industry, as well as the award-winning PBS documentary The Cancer War. He also wrote the first article on alternative medicine for The Encyclopedia Britannica yearbook and the first article on complementary cancer treatments for a medico-legal textbook, Courtroom Medicine: Cancer. With Prof. Josef Beuth of Cologne, he co-edited the first medical textbook in English on non-conventional treatments for cancer, Complementary Oncology (2005).

His articles and scientific communications have appeared in such journals as The Lancet, the Journal of the National Cancer Institute, the Journal of the American Medical Association, New Scientist, Anticancer Research, Genetic Engineering News, Research in Complementary Medicine (Karger), the Journal of Alternative and Complementary Medicine, and Integrative Cancer Therapies (SAGE), of which he is Corresponding Editor. For many years he has written the monthly "War on Cancer" column for the Townsend Letter for Doctors and Patients. His op-ed "Patents Over Patients" appeared in the New York Times in 2007.

Moss was a founding advisor to the National Institutes of Health's Office of Alternative Medicine (now the National Center for Complementary and Alternative Medicine, NCCAM) and to the NIH Cancer Advisory Panel on Complementary and Alternative Medicine (CAP-CAM). He has also been a member of the Advisory Editorial Board of the PDQ System of the National Cancer Institute (NCI). He is a member of the board of directors of the Cancer Prevention Coalition and an advisor to Breast Cancer Action, the Susan J. Komen Breast Cancer Foundation, Life Extension Foundation, RAND Corporation and the Medline-listed journal, Alternative Therapies in Health and Medicine. He has served as an ad hoc reviewer for scientific organizations, including the Czech Academy of Sciences, Current Oncology, the Journal of Research in Medical Science, and the International Journal of Cancer.

Moss has been an invited lecturer at many institutions, including Memorial Sloan-Kettering Cancer Center (Grand Rounds, Surgery, 1999), Howard University Medical School (Grand Rounds, Family Practice, 2003), the University of Arizona Medical Center (Grand Rounds, CAM, 2007), the Department of Energy, American Cancer Society, and many other universities, medical schools and societies in the US and abroad. In 2005 he led the History of Science Seminar at the National Library of Medicine of the National Institutes of Health in Bethesda, MD. He has also received lifetime achievement awards from the American College for the Advancement of Medicine, the Cancer Control Society, the National Foundation for Alternative Medicine, the Wellness Forum, and the Center for Advancement in Cancer Education.

Moss has a particular interest in international developments in integrative oncology. In October 1998, he was made an honorary member and scientific advisor of the German Oncology Society ("DGO"), the first American to be so honored. Since then he has spoken in Germany 10 times, mostly at "Medicine Week" in Baden-Baden, Germany. In 2010 he was appointed a board member of the Italian Association for Research in Integrative Oncological Therapy (ARTOI). Moss visits Canada frequently and in 2010 will speak in Toronto, Nova Scotia and Vancouver. He has given the Coombs Lecture at Foothills Hospital, Calgary, Canada, and at the CAMera conference of the University of Calgary. He has also visited cancer clinics in Germany, Austria, the Czech Republic, Switzerland, Denmark, Italy, Bahamas, Honduras, Canada, China, Great Britain, and most states in the US.

In 2008 he was honored with three visiting professorships in China: at the Shanxi Province Anticancer Research Institute, Chang'An Hospital in Xi'an, and Friendship Hospital in Guangzhou. In 2010 he will visit Israel in collaboration with the foundation Reliable Cancer Therapies, Inc. of Switzerland. He continues to tour clinics around the world looking for better cancer treatments for his readers and clients of the Moss Reports.

Arturo O’Bryne Navia, MD

Arturo O'Byrne Navia obtained his degree as medical doctor in 1977 from Universidad del Cauca in Popayan, Colombia.

He conducted postgraduate studies in Sport Medicine and Nutrition to later become an expert in biological medicine and homotoxicology after several years of study next to German Duque at the Los Robles Clinic in the late 70s and early 80s.

For two decades he has been the director of education for Latin America and Spain of the International Society of Homotoxicology e.V. conducting more than 800 seminaries in Chile, Argentina, Brasil, Ecuador, Venezuela, Panamá, Nicaragua, Honduras, Guatemala, El Salvador, Mexico, USA and Spain while serving as dean of the official clinic for postgraduate studies for that medical society since 1991.

He has been invited continuously as faculty member in postgraduate academic activities of complementary and alternative medicine provided by renamed universities such as Universidades de San Carlos, in Guatemala, Colegio de Médicos y Cirujanos in Puerto Rico, Universidad Complutense de Madrid and Universidad de Valencia, in Spain. His residency in Colombia allows him to take active action in educational events throughout the year and participation in CAM programs at the level of CME, Masters and Certifications for several academic institutions such as Universidad Nacional and Universidad del Bosque in Bogotá; Universidad del Norte in in Barranquilla, CES in Medellín; Universidad Libre in Cali.

Combined with his extensive educational activities he is a member of the board for the International Society of Homotoxicology and Homeopathy in Germany and a fellow member of the Colombian Society of Neural Therapy in Colombia.

He has published two important papers in biological therapy journals under the tittle "Objetivación del efecto orgánico de medicamentos antihomotóxicos mediante el seguimiento segmental - metamérico del leucograma sanguíneo", and "Variaciones clínicas y leucocitarias del biotopograma sanguíneo como respuesta al efecto de bioterapéuticos antihomotóxicos en pacientes con patología crónica del anillo de Waldeyer".

In 2002 he received the Reckeweg Medal Award for his lifetime achievement and contribution in spreading education of Homotoxicology throughout the world.

Robert Jay Rowen, MD

Robert Jay Rowen, MD

Dr. Robert Jay Rowen, a Phi Beta Kappa graduate of Johns Hopkins University and graduate of the University of California, San Francisco School of Medicine is internationally known for his work in the field of complementary/alternative/integrative medicine.

He is affectionately known as the "Father of Medical Freedom" for pioneering the nation's first statutory protection for alternative medicine in 1990 in Alaska, against a concerted opposition from the organized medical community and an imported "quackbuster". A few years later, the Alaska governor appointed him to a term on the state medical board against overwhelming opposition from the medical establishment. His appointment was ultimately confirmed by the legislature with overwhelming public support. The rare medical freedom he enjoyed in Alaska enabled him to greatly expand knowledge and experience in a multitude of disciplines and therapies not normally found in medicine. Jumping into alternative medicine in 1983 through a practice in acupuncture, he quickly expanded to nutritional medicine, chelation therapy, oxidation therapy, homeopathy and herbal medicine, and took intensive training in neural therapy and prolotherapy to help treat and eliminate acute and chronic pain. Alaska's laws enabled him to work extensively with innovative cancer therapies, ozone, and ultraviolet blood irradiation therapy. He is internationally known and respected for training hundreds of open-minded physicians in these techniques from around the world.

In 2001, he became editor in chief of Second Opinion Newsletter, one of the nation's leading monthly publications revealing the frontiers of medicine. Thus, he reduced his practice load considerably to write and teach, and relocated from Alaska to North Bay area, California where he provides part time consultation with his like-minded talented wife, Terri Su, MD.

Olivier Wenker, MD

Olivier Wenker, MD

Professor of Anesthesiology and M. D. Anderson Cancer Center's Director of Technology Discovery
He manages a novel gap fund for the institution. He is triple European board certified in anesthesiology, critical care and emergency/disaster medicine as well as being board certified by the American Board of Anti-Aging and Regenerative Medicine.

Contact Us Today!

Contact Me About: